Infantile hemangioma is a kind of red birthmark, which has the following characteristics: 1, high incidence: it is the most common benign tumor in infants and young children, the incidence rate is as high as 10%; 2, “elimination, growth” has a way: most of the birth of a period of time to find out that within 1 year (especially the first half of the year) growth is rapid, and 1-2 years into the period of regression after birth; 1, “elimination, growth” has a way: most of the hemangiomas are found only after a period of time, and 1 year (especially the first half of the year) growth, and 1 year after the birth of a receding period; 1, Do infants and young children need treatment for hemangioma? Although hemangioma in infants and young children has its own growth law, but it can press and erode the surrounding tissues and organs during the growth period, and cause ulcers, these factors often cause light and heavy damages: (1) Ulcers of hemangiomas in infants and young children with the ulcers incidence rate of 5-21%. The ulcers themselves are traumatic, first of all, they can cause continuous pain, children cry and have difficulty in feeding (lip hemangioma ulcers, children because of the pain affects eating; genital and anal ulcers, because of the pain affects urination and defecation). Secondly, it can cause bleeding, with an incidence of about 41%. In addition, infection can be induced due to the presence of trauma. (2) Appearance damage (pigment loss, scar): due to the infringement of hemangioma itself on the surrounding tissues, the occurrence of ulcers and infections, the normal tissues are damaged, which often leave pigment loss after the late regression, forming a florid appearance, or even forming a scar, affecting the appearance; (3) Functional damage Some tumors develop rapidly, and the large size of the tumor crowds on the surrounding organs, such as periorbital hemangiomas that may For example, periorbital hemangioma may affect the function of eyes. In addition, severe scarring secondary to hemangiomas can pull the surrounding tissues and organs, causing functional impairment. Therefore, although hemangioma in infants and young children has self-limitation, but in order to prevent the occurrence of the above adverse situations, it is necessary to treat it as early as possible. 2.When to treat hemangioma in infants and young children? In view of the rapid development of infantile hemangioma within one year after discovery, especially in the first half of the year, it should be treated as early as possible after discovery, and generally it can be treated at 7 days after birth. 3.Methods of infant hemangioma treatment The treatment of infant hemangioma has made rapid development in the past 5 years, and the treatment plan is also gradually mature: infants and young children need comprehensive treatment according to the situation: (1) Laser treatment: the conventional application is pulsed dye laser, and the newly introduced dual-wavelength laser 585/1064nm laser has shown better therapeutic effect, and the significant effective rate reaches more than 90%. Laser treatment is generally needed throughout the whole course of hemangioma treatment: the initial period can inhibit the growth of hemangioma, the proliferation period can promote the regression of hemangioma, and the elimination period can subside the residual capillary dilatation. In addition, it can accelerate the healing of hemangioma ulcers and reduce pain. (2) Oral drug treatment: now the first choice drug for treating infantile hemangioma is propranolol, whose effectiveness and safety of treatment have been fully recognized in the last 5 years. Secondly, corticosteroid is still an important drug for the treatment of infantile hemangioma, especially for severe hemangioma. (3) Local drug therapy: including injections and topical application of drugs, which is more effective for limited, especially mixed hemangiomas. Commonly used drugs for injection include corticosteroids and antitumor drugs, and commonly used drugs for external application include timolol, imiquimod, etc. (4) Compression therapy: hemangiomas of the limbs can be treated with compression therapy, which makes the hemangiomas relatively ischemic and thus inhibits their development. (5) Surgery: Plastic surgery is often needed when the regression is limited or when improper treatment leaves complications that affect aesthetics and function. (6) Others: Isotope sticker and freezing were popular in the 1980s and 1990s, but have long been abandoned by most organizations due to the complications such as loss of pigment, radioactive ulcers, scarring, and even local dysplasia. Treatment of infantile hemangiomas with nafenolol Hemangiomas are one of the most common benign tumors in infants and children, with an incidence of about 1.1% to 2.6% in newborns. About 2/3 of patients with hemangiomas involve the head and neck. Due to the high incidence of hemangiomas, which may cause a variety of physical and psychological harm to individuals, there are numerous treatment methods, but all of them have certain shortcomings or adverse reactions, especially for the treatment and management of special sites and types of special hemangiomas, which has been a hot spot of clinical and research . In 2008, the French doctor Léeauté -Labrè ze published a communication research paper in the New England Journal of Medicine, reporting their significant discovery of the application of propranolol in the treatment of hemangiomas in infants and children. It has caused a strong reaction among pediatricians, plastic surgeons, dermatologists, dentists, and other physicians, and has become a new option for the pharmacological treatment of hemangiomas. Some more serious and life-threatening hemangiomas in infants and young children can be rapidly controlled after treatment with propranolol. The indications of propranolol for the treatment of infantile hemangioma are: (1) It is mainly used for severe large or head and face lesions. (2) Visual impairment, interference with feeding, and obstruction of the airway due to hemangioma. Possible mechanisms of propranolol treatment of hemangioma are: (1) Down-regulation of hemangioma proliferative factors, such as basic fibroblast growth factor and vascular endothelial growth factor, to promote the regression of hemangioma. (2) Accelerating apoptosis of capillary endothelial cells, causing hemangioma atrophy. (3) Selectively inhibit matrix metalloproteinase-9 and human brain microvascular endothelial cell expression, affecting blood vessel formation, etc. Contraindications to the use of propranolol: asthma, obstructive emphysema is an absolute contraindication. Allergic rhinitis, urticaria, exfoliative dermatitis are relative contraindications. Department of Aesthetic Plastic Surgery has applied propranolol to treat infantile hemangioma since 2010 and achieved good clinical results. Compared with glucocorticoids, propranolol has fewer side effects and is expected to be the first-line drug in the pharmacological treatment of infantile hemangioma.